Evidence map›Paper›PMID 34184823›Full record

ArticleEuropean journal of heart failure2021

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.

William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin and 2 more

2 registry-linked trialsOpen access · bronzeAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719714 phase1 / phase2active not recruitingstarted 2024, after this paper: background citation

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Ran2024Enrolled18Registered outcomes5Posted comparisons0ConditionsChronic Kidney Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Kidney DiseasesArmsDapagliflozin 10 MG [Farxiga]
PMID 29166232PMID 29526832PMID 29133604PMID 29478868PMID 29519950PMID 29121091PMID 29477157PMID 29386200PMID 27692817PMID 28262773PMID 28379378PMID 28874423other papers from this trial
Open the trial in the graph
NCT07700940 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Does The Positive Reno-Protective Effect Of Sodium Glucose Co-Transporter 2 Inhibitors Extend To Lupus Nephritis Population?

TypeinterventionalSponsorAhmed Yehia IsmailRan2024 to 2026Enrolled66ConditionsLupus Nephritis (LN)ArmsEmpagliflozin (25 Mg Tab) along with standard medical therapy, Placebo and standard of care
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Erythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 6 countries.

William G HerringtonMedical Research Council Population Health Research Unit at the University of Oxford, part of the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
Gianluigi SavareseCardiology Unit, Department of Medicine, Karolinska Institute: Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Richard HaynesMedical Research Council Population Health Research Unit at the University of Oxford, part of the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
Nikolaus MarxDepartment of Internal Medicine, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Linda MellbinCardiology Unit, Department of Medicine, Karolinska Institute: Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Lars H LundCardiology Unit, Department of Medicine, Karolinska Institute: Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Paul DendaleHeart Centre Hasselt, Jessa Hospital, Hasselt, Belgium.
Petar SeferovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Giuseppe RosanoDepartment of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
Natalie StaplinMedical Research Council Population Health Research Unit at the University of Oxford, part of the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
Colin BaigentMedical Research Council Population Health Research Unit at the University of Oxford, part of the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
Francesco CosentinoCardiology Unit, Department of Medicine, Karolinska Institute: Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Karolinska University Hospital · SEMedical Research Council · GBUniversity of Oxford · GBIRCCS Ospedale San Raffaele · ITJessa Hospital · BEUniversitätsklinikum Aachen · DEUniversity of Belgrade · RS

Funding

British Heart Foundation CH/1996001/9454Cancer Research UK 16896Medical Research Council MC_U137686849Medical Research Council MC_UU_00017/3Medical Research Council MC_UU_00017/4Medical Research Council MC_UU_12026/6Medical Research Council MR/R007764/1
6 · The paper itself

Abstract

In 2015, the first large-scale placebo-controlled trial designed to assess cardiovascular safety of glucose-lowering with sodium-glucose co-transporter 2 (SGLT2) inhibition in type 2 diabetes mellitus raised hypotheses that the class could favourably modify not only risk of atherosclerotic cardiovascular disease, but also hospitalization for heart failure, and the development or worsening of nephropathy. By the start of 2021, results from 10 large SGLT2 inhibitor placebo-controlled clinical outcome trials randomizing ∼71 000 individuals have confirmed that SGLT2 inhibitors can provide clinical benefits for each of these types of outcome in a range of different populations. The cardiovascular and renal benefits of SGLT2 inhibitors appear to be larger than their comparatively modest effect on glycaemic control or glycosuria alone would predict, with three trials recently reporting that clinical benefits extend to individuals without diabetes mellitus who are at risk due to established heart failure, or albuminuric chronic kidney disease. This European Society of Cardiology position paper summarizes reported results from these 10 large clinical outcome trials considering separately each of the different types of cardiorenal benefit, summarizes key molecular and pathophysiological mechanisms, and provides a synopsis of metabolic effects and safety. We also describe ongoing placebo-controlled trials among individuals with heart failure with preserved ejection fraction and among individuals with chronic kidney disease.

Indexed as

CardiologyDiabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsGlucoseHumansSodiumSodium-Glucose Transporter 2GlucoseSodiumSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular outcomesChronic kidney diseaseHeart failureRandomized controlled trialsSodium-glucose co-transporter 2 inhibitors

Identifiers

PMID34184823
OpenAlexW3175759067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.